Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance
Inspire Medical Systems, a medical technology company (NYSE: INSP), announced preliminary unaudited results for Q4 and full year 2023, with anticipated revenue of $192.3-192.5 million for Q4 and $624.6-624.8 million for full year 2023. The company also provided initial full year 2024 revenue guidance of $775-785 million, showing a 24-26% increase over 2023. Inspire activated 78 new centers in the U.S. and created 13 new sales territories in Q4 2023, demonstrating significant growth and momentum.
Positive
Anticipated revenue increase of approximately 40% for Q4 2023 compared to the same quarter of 2022
Anticipated revenue increase of approximately 53% for full year 2023 compared to 2022
Activated 78 new centers in the U.S. in Q4 2023, bringing the total to 1,180 U.S. medical centers implanting Inspire therapy
Created 13 new sales territories in the U.S. in Q4 2023, bringing the total to 287 U.S. sales territories
Published 2023 Environmental, Social, and Governance (ESG) Report
Initial full year 2024 revenue guidance of $775-785 million, showing a 24-26% increase over 2023
Reviewing the preliminary financial results from Inspire Medical Systems, we see a significant revenue surge, indicating robust growth and market penetration. The reported 40% quarterly and 53% annual revenue increases surpass typical industry averages, suggesting strong demand for their obstructive sleep apnea solutions. This growth trajectory, coupled with the expansion of new centers and sales territories, reflects a strategic scaling of operations which could bolster investor confidence.
The company's forward-looking guidance projects a 24% to 26% revenue increase for 2024 , which is a positive signal for sustained growth, albeit at a slower pace than 2023. Investors should note the potential for operating leverage improvements, as indicated by the CEO's statement on sales growth outpacing operating expenses, possibly leading to higher margins and profitability.
However, the emphasis on preliminary and unaudited figures should be considered with caution. Finalized financials might differ and investors should await the full report for confirmed data. The company's performance against its guidance in the upcoming year will be a critical measure of its ability to maintain growth and manage costs effectively.
Inspire Medical Systems' focus on minimally invasive solutions for obstructive sleep apnea (OSA) is indicative of the increasing demand for innovative healthcare technologies. The activation of 78 new centers and establishment of 13 new sales territories in the U.S. demonstrate the company's aggressive expansion strategy to capture more of the market share in a high-demand sector.
OSA is a prevalent condition with significant unmet medical needs, implying a substantial market opportunity for Inspire. The company's growth reflects not only the effectiveness of its therapy but also the overall market's receptiveness to new medical technologies. As OSA awareness and diagnosis rates increase, Inspire's market potential may expand further, potentially impacting long-term revenue streams.
Investors should also consider the implications of the published Environmental, Social and Governance (ESG) report. As ESG factors become increasingly important to investors, Inspire's commitment to these areas could positively influence its corporate reputation and investor relations.
01/08/2024 - 08:00 AM
MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, and provided its initial full year 2024 guidance.
Preliminary, Unaudited Fourth Quarter and Full Year 2023 Revenue and Recent Business Highlights
Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million , an approximately 40% increase over the same quarter of 2022 Revenue for full year 2023 is anticipated to be in the range of $624.6 million to $624.8 million , an approximately 53% increase over full year 2022 Activated 78 new centers in the U.S. in the fourth quarter of 2023, bringing the total to 1,180 U.S. medical centers implanting Inspire therapy Created 13 new sales territories in the U.S. in the fourth quarter of 2023, bringing the total to 287 U.S. sales territories Published 2023 Environmental, Social, and Governance (ESG) Report Initial Full Year 2024 Revenue Guidance
Revenue for full year 2024 is anticipated to be in the range of $775 million to $785 million , a 24% to 26% increase over full year 2023 “We are very pleased with our strong preliminary revenue performance in the fourth quarter as the team executed exceptionally well and finished the year with significant momentum,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “Throughout 2023, we demonstrated improved operating leverage as our sales growth outpaced operating expenses. As a result, we expect to announce a profitable fourth quarter when we report our full financial results, currently planned for February 6, 2024.”
The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until Inspire reports its full financial results for 2023 in its Annual Report on Form 10-K.
Inspire previously announced its participation in the 41st Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, including a formal company presentation at 7:30 a.m. P.T. on Monday, January 8, 2024.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding our preliminary, unaudited fourth quarter and full year results, and our expectations regarding full year 2024 financial outlook. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID-19 pandemic; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor & Media Contact
Ezgi Yagciezgiyagci@inspiresleep.com
What are the anticipated revenue figures for Inspire Medical Systems for Q4 2023?
Inspire Medical Systems anticipates revenue in the range of $192.3-192.5 million for Q4 2023.
What is the ticker symbol for Inspire Medical Systems?
The ticker symbol for Inspire Medical Systems is INSP.
How many new centers did Inspire Medical Systems activate in the U.S. in Q4 2023?
Inspire Medical Systems activated 78 new centers in the U.S. in Q4 2023.
What is the initial full year 2024 revenue guidance provided by Inspire Medical Systems?
Inspire Medical Systems provided initial full year 2024 revenue guidance of $775-785 million.
What increase in revenue is expected for full year 2024 compared to 2023?
Inspire Medical Systems expects a 24-26% increase in revenue for full year 2024 compared to 2023.
